Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    edited by Dr. Ravin Narain.
    Contents:
    General methods of bioconjugation
    Covalent and noncovalent bioconjugation strategies
    Polymer bioconjugates
    Bioconjugates based on poly(ethylene glycol)s and polyglycerols
    Synthetic polymer bioconjugate systems
    Natural polymer bioconjugate systems
    Dendrimer bioconjugates: synthesis and applications
    Organic nanoparticles based bioconjugates
    Bioconjugation strategies: lipids, liposomes, polymersomes, and microbubbles
    Organic nanoparticle bioconjugate: micelles, cross-linked micelles, and nanogels
    Carbon nanotubes and fullerene C60 bioconjugates
    Inorganic nanomaterials bioconjugates (metals, metal oxides--quantum dots, iron-oxide)
    Gold nanomaterials bioconjugates
    Methods for magnetic nanoparticle synthesis and functionalization
    Quantum dots bioconjugates
    Silica nanoparticle bioconjugates
    Polyhedral oligomeric silsesquioxanes (POSS) bioconjugates
    Cell-based, hydrogels/microgels and glyco-bioconjugates
    Cell-based bioconjugates
    Bioresponsive hydrogels and microgels
    Conjugation strategies used for the preparation of carbohydrate-conjugate vaccines
    Characterization, physico-(bio)chemical properties, and applications of bioconjugates
    Properties and characterization of bioconjugates
    Physico-chemical and biochemical properties of bioconjugates
    Applications of bioconjugates.
    Digital Access Wiley 2014
  • Article
    Giansiracusa JE, Donaldson MS, Koonce ML, Lefton TE, Ruoff GE, Brooks CD.
    South Med J. 1977 Jan;70(1):49-52.
    In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo. Each treatment was given for four weeks. Considering relief of pain, ability to function, and general well-being, the patients preferred drug to placebo, usually by a statistically significant margin. Combined results showed no significant differences between ibuprofen and aspirin. Patients' evaluations of exercise-related pain, ability to perform a selected activity, and total discomfort and disability, and physicians' evaluations of discomfort and disability, all favored drug over placebo, and the differences were significant for a number of endpoints. The results indicated ibuprofen, 1,800 mg/day, offers about the same antiarthritic benefit as aspirin, 3,600 mg/day. Both drugs are superior to placebo. The incidence of gastrointestinal complaints with ibuprofen was similar to that with placebo and significantly lower than that with aspirin.
    Digital Access Access Options